Form 4: TransMedics Group CFO Stephen Gordon Executes Stock Option and Sells Shares

Stephen Gordon, CFO of TransMedics Group, exercised stock options and sold 15,000 shares of common stock on April 1, 2024, according to a recent SEC filing.

Summary

• On April 1, 2024, Stephen Gordon, the Chief Financial Officer of TransMedics Group, Inc., executed a stock option to acquire 15,000 shares of common stock at a price of $38.46 per share.
• Simultaneously, Gordon sold 15,000 shares of TransMedics Group common stock at a price of $74.01 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on September 14, 2023.
• Following these transactions, Gordon directly owns 23,299 shares of TransMedics Group common stock.
• Gordon also holds options to purchase 37,477 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity under a pre-arranged plan. There's no indication of positive or negative sentiment towards the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates any significant concerns.

Key Dates